Seminars in Hematology
Volume 44, Issue 4 , Pages 220-226, October 2007

Activity Survey and Historical Perspective of Autologous Stem Cell Transplantation in Europe

  • Alois Gratwohl

      Affiliations

    • Corresponding Author InformationAddress correspondence to Alois Gratwohl, MD, Hematology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.

European Group for Blood and Marrow Transplantation Activity Survey Hematology, University Hospital Basel, Switzerland.

Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignancies that are responsive to high-dose chemoradiotherapy. Autologous HSCTs are the standard of care for defined patients with lymphoid malignancies and for certain solid tumors of childhood. They continue to be evaluated in acute myeloid leukemia and are being investigated in phase II and III studies for defined severe autoimmune disorders. More than 15,000 such procedures, mainly peripheral blood stem cell transplants, are performed annually in Europe, which corresponds to double the number of allogeneic HSCTs. These numbers emphasize the important role of this type of therapy at its current stage.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the European Leukemia Net LSH-2002-2.2.0-3 and the Swiss National Research Foundation 3200 BO-106 105/1 and by Oncosuisse. See Acknowledgment for complete list of funding.

PII: S0037-1963(07)00127-8

doi:10.1053/j.seminhematol.2007.09.001

Seminars in Hematology
Volume 44, Issue 4 , Pages 220-226, October 2007

Article Tools

* Image Usage & Resolution